Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppressionFederico Pulido, José Ramón Arribas, Ignacio Valero et al.|Antiviral Therapy|2009Cited by 60
Documento de consenso: Recomendaciones para el manejo de la enfermedad ósea metabólica en pacientes con virus de la inmunodeficiencia humanaEstebán Martínez, Manuel Muñoz‐Torres, Esteban Jódar Gimeno et al.|Enfermedades Infecciosas y Microbiología Clínica|2013Cited by 8
Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive StudyDaniel Podzamczer, The TORAL Study Group, Estebán Martínez et al.|Current HIV Research|2012Cited by 3
Lack of association between loneliness, social isolation and inflammation in people living with HIV aged ≥50 years: Results from the sub-study “No One Alone-Gesida Study”José Ramón Blanco, Verónica Pérez‐Esquerdo, Inmaculada González‐Cuello et al.|PLoS ONE|2025Cited by 0